摘要
The recent manuscript in New England Journal of Medicine by Antonarakis et al. has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 （AR-V7）, in circulating tumor cells （CTCs） from metastatic castrate-resistant prostate cancer （mCRPC） patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen （PSA） responses.
The recent manuscript in New England Journal of Medicine by Antonarakis et al. has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 （AR-V7）, in circulating tumor cells （CTCs） from metastatic castrate-resistant prostate cancer （mCRPC） patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen （PSA） responses.
